Literature DB >> 22258775

Five-year results of the ASR XL Acetabular System and the ASR Hip Resurfacing System: an analysis from the Australian Orthopaedic Association National Joint Replacement Registry.

Richard N de Steiger1, Jacqueline R Hang, Lisa N Miller, Stephen E Graves, David C Davidson.   

Abstract

BACKGROUND: Articular Surface Replacement (ASR) hip prostheses, which have metal-on-metal bearing surfaces, were manufactured by DePuy Orthopaedics (Warsaw, Indiana) for use in both conventional total hip arthroplasty and hip resurfacing. Both the ASR XL Acetabular System and the ASR Hip Resurfacing System were recently recalled worldwide by the manufacturer. This report summarizes an analysis by the Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR) of the outcome of arthroplasties involving the ASR prostheses.
METHODS: The first recorded use of the ASR XL Acetabular System in Australia occurred in 2004, and the Registry recorded 4406 procedures involving this system through December 31, 2009. The first recorded use of the ASR Hip Resurfacing System in Australia occurred in 2003, and the Registry recorded 1167 procedures through December 31, 2009. The Kaplan-Meier method and proportional-hazard modeling were used to compare the revision rate of primary total hip arthroplasties involving the ASR XL Acetabular System with that of arthroplasties involving all other conventional prostheses as well as with that of arthroplasties involving all other conventional prostheses with a metal-on-metal-articulation. In addition, the revision rate of primary arthroplasties involving the ASR Hip Resurfacing System was compared with that of arthroplasties involving all other hip resurfacing prostheses. Patient demographics, prosthesis characteristics, and information regarding the type of revision and the reason for revision were also compared.
RESULTS: Arthroplasties involving both ASR designs had a significantly greater revision rate compared with those involving all other prostheses. The cumulative revision rate of arthroplasties involving the ASR XL Acetabular System at five years postoperatively was 9.3% (95% confidence interval [CI], 7.3% to 11.9%) compared with 3.4% (95% CI, 3.3% to 3.5%) for total hip arthroplasties involving all other conventional prostheses. The cumulative revision rate of arthroplasties involving the ASR Hip Resurfacing System at five years postoperatively was 10.9% (95% CI, 8.7% to 13.6%) compared with 4.0% (95% CI, 3.7% to 4.5%) for arthroplasties involving all other resurfacing prostheses. Arthroplasties involving the ASR XL Acetabular System had a greater rate of revision due to implant loosening and/or osteolysis and due to metal sensitivity compared with total hip arthroplasties involving all other conventional prostheses. Arthroplasties involving the ASR XL Acetabular System also had a significantly greater revision rate compared with total hip arthroplasties involving all other conventional metal-on-metal prostheses. Arthroplasties involving the ASR Hip Resurfacing System had a greater rate of revision due to metal sensitivity compared with total hip arthroplasties involving all other resurfacing prostheses.
CONCLUSIONS: ASR prostheses used in conventional hip arthroplasty and in hip resurfacing exhibited a greater revision rate compared with other prostheses in the AOANJRR. These results are consistent with those derived from other registries and from published studies of individual cohorts.

Entities:  

Mesh:

Year:  2011        PMID: 22258775     DOI: 10.2106/JBJS.J.01727

Source DB:  PubMed          Journal:  J Bone Joint Surg Am        ISSN: 0021-9355            Impact factor:   5.284


  59 in total

1.  Large-diameter metal-on-metal total hip arthroplasty: dislocation infrequent but survivorship poor.

Authors:  Adolph V Lombardi; Keith R Berend; Michael J Morris; Joanne B Adams; Michael A Sneller
Journal:  Clin Orthop Relat Res       Date:  2014-11-04       Impact factor: 4.176

2.  What is the learning curve for the anterior approach for total hip arthroplasty?

Authors:  Richard Noel de Steiger; Michelle Lorimer; Michael Solomon
Journal:  Clin Orthop Relat Res       Date:  2015-12       Impact factor: 4.176

3.  CORR Insights ®: High prevalence of adverse reactions to metal debris in small-headed ASR™ hips.

Authors:  William Macaulay
Journal:  Clin Orthop Relat Res       Date:  2013-06-21       Impact factor: 4.176

4.  Revisions of monoblock metal-on-metal THAs have high early complication rates.

Authors:  Louis S Stryker; Susan M Odum; Thomas K Fehring; Bryan D Springer
Journal:  Clin Orthop Relat Res       Date:  2015-02       Impact factor: 4.176

5.  A decade of Australian and New Zealand orthopaedic publications: a bibliometric trend analysis from 2008 to 2018.

Authors:  Agesilaus W Churchill; Eva Malacova; Simon F Journeaux; Martin Richardson; Ross Crawford; Mark L Vickers
Journal:  Int Orthop       Date:  2019-06-26       Impact factor: 3.075

6.  CORR Insights®: What Is the Risk of Repeat Revision When Patellofemoral Replacement Is Revised to TKA? An Analysis of 482 Cases From a Large National Arthroplasty Registry.

Authors:  Brian R Hallstrom
Journal:  Clin Orthop Relat Res       Date:  2019-06       Impact factor: 4.176

7.  Medium term review of the ASR implant system: A single surgeon series.

Authors:  M Curtin; E Murphy; C Bryan; D Jadaan; M Jadaan; D Bergin; C G Murphy; W Curtin
Journal:  J Orthop       Date:  2017-02-03

8.  Patient views on financial relationships between surgeons and surgical device manufacturers.

Authors:  Mark W Camp; Allan E Gross; Martin F McKneally
Journal:  Can J Surg       Date:  2015-10       Impact factor: 2.089

Review 9.  Metal-on-metal hip resurfacing arthroplasty: an analysis of safety and revision rates.

Authors:  S Sehatzadeh; K Kaulback; L Levin
Journal:  Ont Health Technol Assess Ser       Date:  2012-08-01

10.  Long-term results of Birmingham hip resurfacing arthroplasty in Asian patients.

Authors:  Keisuke Uemura; Masaki Takao; Hidetoshi Hamada; Takashi Sakai; Kenji Ohzono; Nobuhiko Sugano
Journal:  J Artif Organs       Date:  2017-08-30       Impact factor: 1.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.